Last reviewed · How we verify
Solifenacin plus Tamsulosin
Solifenacin blocks muscarinic receptors in the bladder to reduce overactive bladder symptoms, while tamsulosin relaxes smooth muscle in the prostate and urethra to improve urinary flow.
Solifenacin blocks muscarinic receptors in the bladder to reduce overactive bladder symptoms, while tamsulosin relaxes smooth muscle in the prostate and urethra to improve urinary flow. Used for Overactive bladder with urinary urgency, frequency, and incontinence in patients with benign prostatic hyperplasia, Lower urinary tract symptoms associated with benign prostatic hyperplasia.
At a glance
| Generic name | Solifenacin plus Tamsulosin |
|---|---|
| Also known as | Vesicare, Harnal |
| Sponsor | Soonchunhyang University Hospital |
| Drug class | Anticholinergic agent + alpha-1A adrenergic antagonist combination |
| Target | M3 muscarinic receptor; alpha-1A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Solifenacin is an anticholinergic agent that selectively antagonizes M3 muscarinic receptors on bladder detrusor muscle, decreasing involuntary contractions and urinary urgency. Tamsulosin is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, reducing urinary obstruction and improving flow rate. Together, they address both storage and voiding symptoms in benign prostatic hyperplasia with concurrent overactive bladder.
Approved indications
- Overactive bladder with urinary urgency, frequency, and incontinence in patients with benign prostatic hyperplasia
- Lower urinary tract symptoms associated with benign prostatic hyperplasia
Common side effects
- Dry mouth
- Constipation
- Dizziness
- Headache
- Blurred vision
- Urinary retention
Key clinical trials
- Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin.
- Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms (PHASE3)
- Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (PHASE3)
- Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB (PHASE4)
- Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH (PHASE3)
- Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms (PHASE4)
- Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia (PHASE3)
- Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Solifenacin plus Tamsulosin CI brief — competitive landscape report
- Solifenacin plus Tamsulosin updates RSS · CI watch RSS
- Soonchunhyang University Hospital portfolio CI